Old Web
English
Sign In
Acemap
>
authorDetail
>
J.C.L Himmelreich
J.C.L Himmelreich
Medicine
Internal medicine
Rivaroxaban
Cardiology
Apixaban
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Comparing rivaroxaban and apixaban in GARFIELD-AF according to ROCKET AF and ARISTOTLE trial selection criteria
2021
European Heart Journal
J.C.L Himmelreich
Saverio Virdone
Alan John Camm
Ralf E. Harskamp
Karen S. Pieper
K. A. A. Fox
J. P. Bassand
David Fitzmaurice
Samuel Z. Goldhaber
Shinya Goto
Sylvia Haas
Frank Misselwitz
A.G.G. Turpie
Freek W.A. Verheugt
Ajay K. Kakkar
Garfield-Af Investigators
Show All
Source
Cite
Save
Citations (0)
Comparative effectiveness of NOAC vs VKA in patients representing common clinical challenges: results from the GARFIELD-AF registry
2021
European Heart Journal
Saverio Virdone
J.C.L Himmelreich
Karen S. Pieper
Alan John Camm
J. P. Bassand
K. A. A. Fox
David Fitzmaurice
Samuel Z. Goldhaber
Shinya Goto
Sylvia Haas
Gloria Kayani
Frank Misselwitz
A.G.G. Turpie
Freek W.A. Verheugt
Ajay K. Kakkar
Garfield-Af Investigators
Show All
Source
Cite
Save
Citations (0)
Safety and efficacy of apixaban and rivaroxaban versus warfarin in real-world atrial fibrillation patients are similar to their randomized trials: insights from GARFIELD-AF registry
2021
European Heart Journal
J.C.L Himmelreich
Saverio Virdone
Alan John Camm
Ralf E. Harskamp
Karen S. Pieper
K. A. A. Fox
J. P. Bassand
David Fitzmaurice
Samuel Z. Goldhaber
Shinya Goto
Sylvia Haas
Frank Misselwitz
A.G.G. Turpie
Freek W.A. Verheugt
Ajay K. Kakkar
Garfield-Af Investigators
Show All
Source
Cite
Save
Citations (0)
1